Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis.

Abstract

This study evaluated the efficacy of the interleukin-17A inhibitor secukinumab in patients with oligoarticular psoriatic arthritis (PsA). A total of 84 patients with oligoarticular PsA, defined as 1-4 tender joints and 1-4 swollen joints, were pooled from the FUTURE2-5 and MAXIMISE trials (NCT01752634, NCT01989468, NCT02294227, NCT02404350, and NCT02721966). Patients were grouped by treatment received at week12 (secukinumab 300mg, secukinumab 150mg, or placebo) and week52 (any secukinumab 300mg or any secukinumab 150mg). Efficacy was assessed by the proportion of patients achieving selected clinical outcomes. The predictors of Disease Activity index for Psoriatic Arthritis (DAPSA) responses at weeks12 and 52 were identified by logistic regression analysis. Secukinumab treatment resulted in greater achievement of DAPSA-based low disease activity (LDA), DAPSA-based remission (REM), DAPSA50, and DAPSA75 than placebo at week12, with improvements sustained or further increased through week52. LDA or REM was achieved at week52 by more than 90% of patients who received either secukinumab dose, although secukinumab 300mg resulted in the highest achievement of the stringent DAPSA75 and DAPSA REM outcomes. At week12, younger age was associated with DAPSA LDA or REM and DAPSA50, while lower baseline swollen joint count was associated with DAPSA REM. No predictors were identified at week52. The safety profile was consistent with the full study populations. Secukinumab demonstrated efficacy vs placebo across several outcome measures in patients with oligoarticular PsA at week12, with sustained or improved responses through week52.